Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer

Executive Summary

Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.

Advertisement

Related Content

The Year's Clinical Trials In Review: Big Hits In 2017
Keeping Track: Approvals, A Burst Of Submissions, And Some Priority Reviews
Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer
Pipeline Watch: Phase III Readouts For Alectinib and Omadacycline
Under Fire, Bristol Plans To Pick Up The IO Pieces
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
What's Next For Bristol's Opdivo/Yervoy Combination
BMS' Opdivo/Yervoy OK'd; 1st U.S. Immuno-Oncology Combo

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099323

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel